Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 26, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs for Dr. R G Greig on March 24, 2008, at a price of $42.14 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: March 24, 2008.
- Individual Involved: Dr. R G Greig.
- Transaction Type: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.
- Price per ADR: $42.14.
- Reporting Date: March 26, 2008.